These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 20346254

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Therapy of calcinosis universalis complicating adult dermatomyositis.
    Terroso G, Bernardes M, Aleixo A, Madureira P, Vieira R, Bernardo A, Costa L.
    Acta Reumatol Port; 2013; 38(1):44-8. PubMed ID: 24131911
    [Abstract] [Full Text] [Related]

  • 7. Treatment of calcinosis in juvenile dermatomyositis with probenecid: the role of phosphorus metabolism in the development of calcifications.
    Harel L, Harel G, Korenreich L, Straussberg R, Amir J.
    J Rheumatol; 2001 May; 28(5):1129-32. PubMed ID: 11361202
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of probenecid for a patient with juvenile dermatomyositis complicated with calcinosis.
    Nakamura H, Kawakami A, Ida H, Ejima E, Origuchi T, Eguchi K.
    J Rheumatol; 2006 Aug; 33(8):1691-3. PubMed ID: 16881125
    [Abstract] [Full Text] [Related]

  • 9. Metaphyseal sclerosis associated with bisphosphonate therapy.
    Damiani D.
    J Pediatr Endocrinol Metab; 2007 Nov; 20(11):1167. PubMed ID: 18183786
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta.
    Land C, Rauch F, Glorieux FH.
    J Bone Miner Res; 2006 Mar; 21(3):374-9. PubMed ID: 16491284
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards.
    Poyrazoglu S, Gunoz H, Darendeliler F, Bas F, Tutunculer F, Eryilmaz SK, Bundak R, Saka N.
    J Pediatr Orthop; 2008 Jun; 28(4):483-7. PubMed ID: 18520289
    [Abstract] [Full Text] [Related]

  • 17. Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis.
    Heijckmann AC, Juttmann JR, Wolffenbuttel BH.
    Neth J Med; 2002 Sep; 60(8):315-9. PubMed ID: 12481878
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.